Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases.
The last earnings update was 77 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Organovo Holdings. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Organovo Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
Organovo Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
Organovo Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Organovo Holdings's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Organovo Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
Organovo Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Organovo Holdings's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Organovo Holdings's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Organovo Holdings has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Taylor J. Crouch has been Chief Executive Officer and President of Organovo Holdings, Inc. since April 25, 2017. Mr. Crouch served as Chief Executive Officer of eStudySite, Inc. until April 2017. Mr. Crouch has 25 years of drug development and commercialization experience spanning large pharmaceutical companies, biotech and the CRO industry. Mr.Crouch served as Senior Vice President of Operations & Supply Operations and President of International of Ligand Pharmaceuticals Incorporated since May 2005. Prior to joining Ligand in May 2005, Mr. Crouch served as President and Chief Operating Officer of Discovery Partners International Inc. from July 2002 to January 2005. From April 1999 to April 2002, he served as President and Chief Executive Officer of Variagenics Inc. From January 1991 to March 1999, he served as the Senior Vice President of Worldwide Marketing and Strategic Development of PAREXEL International Corp. He held various positions for over ten years with Schering-Plough International and Pfizer. He has been Director of Organovo Holdings, Inc. since April 25, 2017. He has been Director of BIOCOM, Inc. since May 31, 2018. He served as a Director of Bruker AXS, Inc. since November 2000. He served as an Independent Director of Bruker Corporation from July 2003 to May 16, 2007. From April 1999 to April 2002, he served as a Director of Variagenics, Inc. Mr. Crouch has a B.S. in Chemical Engineering, cum laude, from Princeton University and an M.B.A. in International Finance and Marketing from the University of Chicago.
Insufficient data for Taylor to compare compensation growth.
Taylor's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Organovo Holdings management team is about average.
CEO, President & Director
Chief Financial Officer
VP of Investor Relations & Corporate Communications
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Organovo Holdings board of directors is about average.
Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.